Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paracrine Induction of Cardiomyogenic Differentiation in Patient-Specific MSCs Using Conditioned Medium from iPSC-CMs.

Biomedicines·2026
Same author

Refining fibroblast-to-cardiomyocyte transdifferentiation protocols to explore emergent self-organization in cardiac cultures.

PloS one·2026
Same author

Quantifying Early Electromechanical Integration of Cardiomyocytes Using a Minimalist PCL Nanofiber Platform.

Polymers·2026
Same author

Biomimetic Cardiac Tissue Models for In Vitro Arrhythmia Studies.

Biomimetics (Basel, Switzerland)·2023
Same author

Novel Molecular Vehicle-Based Approach for Cardiac Cell Transplantation Leads to Rapid Electromechanical Graft-Host Coupling.

International journal of molecular sciences·2023
Same author

Polymer Kernels as Compact Carriers for Suspended Cardiomyocytes.

Micromachines·2023

Related Experiment Video

Updated: May 12, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

Advanced Cardiovascular Toxicity Screening: Integrating Human iPSC-Derived Cardiomyocytes with 2D In Silico Models.

Anastasiya Sinitsyna1, Andrey Berezhnoy1,2,3, Ivan Semidetnov1

  • 1Laboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, 141701.

Cardiovascular Toxicology
|March 28, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces an integrated platform using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and computer models for advanced cardiac safety screening. It predicts drug-induced cardiac risks by analyzing electrophysiological changes, improving safety assessments.

Keywords:
ArrhythmiaCardiac tissueComputer modelingExcitation waveInduced pluripotent stem cellsReentry

More Related Videos

Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes
05:06

Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes

Published on: May 5, 2020

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Related Experiment Videos

Last Updated: May 12, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes
05:06

Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes

Published on: May 5, 2020

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Area of Science:

  • Cardiovascular Pharmacology
  • Stem Cell Technology
  • Computational Biology
  • Drug Safety Assessment

Background:

  • The pharmaceutical industry is transitioning towards advanced methods for in vitro cardiac safety screening.
  • Traditional reliance on QT-interval prolongation for arrhythmogenicity is insufficient.
  • The Comprehensive In Vitro Proarrhythmia Assay (CiPA) advocates for integrated in silico and in vitro approaches.

Purpose of the Study:

  • To develop and validate an innovative platform for assessing drug-induced arrhythmogenicity.
  • To integrate in vitro human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) assays with in silico computer modeling.
  • To evaluate drug effects on ionic currents and intercellular coupling for comprehensive cardiac risk assessment.

Main Methods:

  • Utilized hiPSC-CM for in vitro propagation testing.
  • Developed in silico models incorporating hiPSC-CM electrophysiological and morphological data.
  • Integrated experimental data with computational simulations to assess drug-induced arrhythmogenic potential.

Main Results:

  • The integrated platform successfully predicted clinical manifestations of drug side effects.
  • Demonstrated accurate assessment of drug impacts on ionic currents and electrophysiological coupling using lidocaine and Cyclophosphamide as examples.
  • Showcased the platform's capability to identify potential cardiac risks associated with specific drug concentrations.

Conclusions:

  • An integrative experimental and computer modeling platform offers a more comprehensive approach to cardiac safety screening.
  • This novel approach can predict drug-induced cardiac risks by analyzing electrophysiological changes in hiPSC-CM.
  • The platform facilitates early detection of potential adverse cardiac events, enhancing drug development safety.